RXRX vs. IBB
RXRX (Recursion Pharmaceuticals, Inc.) is a stock, while IBB (iShares Nasdaq Biotechnology ETF) is Health & Biotech Equities fund tracking the NASDAQ Biotechnology Index. Over the past 5 years, RXRX returned -38.02%/yr vs 3.63%/yr for IBB. A 0.58 correlation means they provide meaningful diversification when combined.
Performance
RXRX vs. IBB - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, RXRX achieves a -26.16% return, which is significantly lower than IBB's 12.39% return.
RXRX
- 1D
- -8.76%
- 1M
- -5.03%
- 6M
- -34.91%
- YTD
- -26.16%
- 1Y
- -43.97%
- 3Y*
- -39.15%
- 5Y*
- -38.02%
- 10Y*
- —
IBB
- 1D
- -0.21%
- 1M
- 10.54%
- 6M
- 11.21%
- YTD
- 12.39%
- 1Y
- 44.83%
- 3Y*
- 13.93%
- 5Y*
- 3.63%
- 10Y*
- 7.87%
RXRX vs. IBB - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
RXRX Recursion Pharmaceuticals, Inc. | -26.16% | -39.50% | -31.44% | 27.89% | -54.99% | -42.90% |
IBB iShares Nasdaq Biotechnology ETF | 12.39% | 27.98% | -2.41% | 3.76% | -13.69% | -0.26% |
Correlation
The correlation between RXRX and IBB is 0.52, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.52 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.57 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.60 |
Correlation (All Time) Calculated using the full available price history since Apr 16, 2021 | 0.58 |
The correlation between RXRX and IBB has been stable across timeframes, ranging from 0.52 to 0.60 - a consistent structural relationship.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
RXRX vs. IBB — Risk / Return Rank
RXRX
IBB
RXRX vs. IBB - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Recursion Pharmaceuticals, Inc. (RXRX) and iShares Nasdaq Biotechnology ETF (IBB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| RXRX | IBB | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.83 | ||
| Sortino ratioReturn per unit of downside risk | -3.78 | ||
| Omega ratioGain probability vs. loss probability | 0.93 | 1.37 | -0.44 |
| Calmar ratioReturn relative to maximum drawdown | -0.76 | 4.68 | -5.43 |
| Martin ratioReturn relative to average drawdown | -1.13 | 14.24 | -15.37 |
Loading charts...
Drawdowns
RXRX vs. IBB - Drawdown Comparison
The maximum RXRX drawdown since its inception was -93.13%, which is greater than IBB's maximum drawdown of -62.85%. Use the drawdown chart below to compare losses from any high point for RXRX and IBB.
Loading charts...
Drawdown Indicators
| RXRX | IBB | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.13% | -62.85% | -30.28% |
Max Drawdown (1Y)Largest decline over 1 year | -58.17% | -9.63% | -48.54% |
Max Drawdown (3Y)Largest decline over 3 years | -82.09% | -24.85% | -57.24% |
Max Drawdown (5Y)Largest decline over 5 years | -92.11% | -39.82% | -52.29% |
Max Drawdown (10Y)Largest decline over 10 years | — | -39.82% | — |
Current DrawdownCurrent decline from peak | -92.69% | -4.40% | -88.29% |
Average DrawdownAverage peak-to-trough decline | -75.65% | -21.09% | -54.56% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 38.98% | 3.16% | +35.82% |
Volatility
RXRX vs. IBB - Volatility Comparison
Recursion Pharmaceuticals, Inc. (RXRX) has a higher volatility of 18.33% compared to iShares Nasdaq Biotechnology ETF (IBB) at 5.93%. This indicates that RXRX's price experiences larger fluctuations and is considered to be riskier than IBB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| RXRX | IBB | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 18.33% | 5.93% | +12.40% |
Volatility (6M)Calculated over the trailing 6-month period | 46.55% | 15.91% | +30.64% |
Volatility (1Y)Calculated over the trailing 1-year period | 70.57% | 20.51% | +50.06% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 93.34% | 22.13% | +71.21% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 93.21% | 23.13% | +70.08% |
Dividends
RXRX vs. IBB - Dividend Comparison
RXRX has not paid dividends to shareholders, while IBB's dividend yield for the trailing twelve months is around 0.22%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
IBB iShares Nasdaq Biotechnology ETF | 0.22% | 0.23% | 0.29% | 0.26% | 0.31% | 0.21% | 0.21% | 0.33% | 0.20% | 0.30% | 0.19% | 0.03% |
RXRX Recursion Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Frequently Asked Questions
RXRX and IBB have a correlation of 0.52, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
RXRX has higher volatility (18.33%) compared to IBB (5.93%). In terms of maximum drawdown, RXRX dropped -93.13% vs IBB's -62.85%.
IBB currently has the higher Sharpe Ratio (2.20 vs -0.63), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for RXRX and IBB
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer